Ipca Laboratories Limited
IPCALAB
Hisse Senetlerindeki Sıralama
#3417
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures... Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Hisse Fiyatı
$20.02
Son senkronizasyon: 2026-10-19
Piyasa Değeri
$5.08B
Değişim (1 gün)
-1.65%
Değişim (1 yıl)
37.56%
Ülke
IN
Ticaret Ipca Laboratories Limited (IPCALAB)
Kategori
Healthcare
Ipca Laboratories Limited (IPCALAB) için gelir
Jun 2026 itibarıyla gelir TTM: $1.12B
Ipca Laboratories Limited şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) $1.12B'dir. 2024 yılında şirketin geliri $924.15M önceki yıla göre artış 2023 yılındaki $760.29M gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Ipca Laboratories Limited için 2005 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
| Yıl | Gelir | Değiştir |
|---|---|---|
| 2026 (TTM) | $1.12B | 6.89% |
| 2025 | $1.05B | 13.12% |
| 2024 | $924.15M | 21.55% |
| 2023 | $760.29M | -1.02% |
| 2022 | $768.09M | 3.73% |
| 2021 | $740.50M | 19.97% |
| 2020 | $617.22M | 13.54% |
| 2019 | $543.63M | 7.74% |
| 2018 | $504.56M | 3.67% |
| 2017 | $486.70M | 12.46% |
| 2016 | $432.77M | -14.12% |
| 2015 | $503.92M | -7.96% |
| 2014 | $547.51M | 5.75% |
| 2013 | $517.74M | 11.30% |
| 2012 | $465.16M | 9.12% |
| 2011 | $426.30M | 22.77% |
| 2010 | $347.24M | 37.32% |
| 2009 | $252.88M | -3.75% |
| 2008 | $262.72M | 21.27% |
| 2007 | $216.64M | 27.04% |
| 2006 | $170.53M | 9.66% |
| 2005 | $155.51M | 0.00% |
Benzer şirketler veya rakiplerin geliri
| Şirket | Gelir | Gelir Farkı | Ülke |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 491.67% |
IN
|
